195990 — ABPro Bio Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩146bn
- KR₩139bn
- KR₩25bn
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 14,967 | 30,885 | 53,961 | 21,038 | 18,929 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 10,765 | 5,013 | 4,331 | 4,554 | 6,113 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 81,426 | 57,808 | 81,903 | 45,793 | 44,804 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 49,738 | 39,552 | 24,170 | 23,099 | 22,579 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 202,871 | 166,028 | 167,884 | 156,646 | 142,110 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 64,265 | 14,831 | 29,760 | 16,009 | 17,925 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 85,426 | 26,928 | 30,343 | 16,450 | 19,769 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 117,445 | 139,100 | 137,541 | 140,196 | 122,340 |
Total Liabilities & Shareholders' Equity | 202,871 | 166,028 | 167,884 | 156,646 | 142,110 |
Total Common Shares Outstanding |